EFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer

The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers... | April 11, 2023

Related Keywords

United States ,Doug Warner ,Christopherm Calabrese ,Kevin Gardner ,Christina Curtis ,Jennifer Caswell Jin ,Mike Tattory ,Exchange Commission ,Lifesci Communications ,Nasdaq ,Pfizer ,Effector Therapeutics Inc ,Assistant Professor ,Stanford Medicine ,Biomedical Data Science ,Artificial Intelligence ,Cancer Genomics ,Private Securities Litigation Reform Act ,Effector Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,The ,If4a ,Hill ,He ,Tested ,N ,Specific ,Ncluding ,Standard ,Risk ,Patients ,Us ,Fell ,Carrying ,Pecific Eftr Us28202v1089 ,